Chronic infection with hepatitis C virus (HCV) is related to monoclonal B-cell lymphoproliferative disorders including a benign monoclonal lymphoproliferation such as type II mixed cryoglobulinemia, and B-cell non-Hodgkin's lymphomas (NHL).
Monoclonal B cells in both mixed cryoglobulinemia and HCV-associated NHL frequently express an idiotype encoded by the VH1-69 heavy chain and the kv325 light chain variable genes, 1 a putative signature for anti-HCV specificity. The pathogenesis of HCV-related lymphomas is probably similar to that of other infection-driven marginal zone B-cell lymphomas, for example, mucosa associated lymphoid tissue (MALT) lymphomas associated with Helicobacter pylori infection. 2 Lymphoma regression after eradication of infection by antiviral treatment is major evidence in support of HCV playing an etiological role in B-cell NHL. 3 Although the molecular and cytogenetic features of H. pyloriassociated MALT lymphomas have been investigated in depth, genetic information on HCV-associated lymphomas is limited to a debated role for IgH/BCL2 rearrangement. 4 Here we provide new molecular cytogenetic insights into HCV-associated B-cell NHL. The findings were subsequently sought in patients with HCV-positive mixed cryoglobulinemia in order to identify common genetic pathways between mixed cryoglobulinemia and B-cell NHL.
We recruited 16 HCV-positive NHL patients (5 men and 11 women, median age 70 years; range 41-82) and 19 cases of type II mixed cryoglobulinemia without lymphoma (4 men and 15 women, median age 70 years; range 32-82). There were nine cases of marginal zone lymphoma (MZL) ( Table 1) , six of which were splenic MZL (cases 1-6), and two cases showing a concomitant large cell component (cases 8 and 9); three cases of large B-cell lymphoma (LBCL, cases 10-12); three cases of small lymphocytic lymphoma (SLL, cases 13-15); and one case of lymphoplasmacytic lymphoma (LPL, case 16). Seven of the 12 patients who were tested also presented mixed cryoglobulinemia. In 11/11 cases, tumor cells expressed CD27, a marker for memory/mutated B cells. Flow cytometry analysis revealed that in 5/10 cases tumor cells expressed the kv325 and/or VH1-69 genes (Supplementary Information 1).
Metaphase and/or array-CGH analyses were performed in 14 cases. Eleven (78%) showed at least one copy number alteration (Table1 and Figure 1a ). Five patients (cases 2, 8, 10, 11 and 13) had complex (X3) chromosome imbalances. A total of 61 genomic imbalances included 32 gains and 29 losses. The most frequent gains involved chromosomes 1 and 3, namely 1q and 3q (three cases each, 8, 11, 13 and 1-3, respectively). Chromosome 2 was most frequently involved in losses, with four cases showing a deletion at the long arm (cases 8, 9, 10 and 13) and one showing loss of the entire chromosome (case 11). 1q gain was always associated with a 2q loss, while 2q loss and 3q gain were mutually exclusive. Other recurrent abnormalities were gains of 6p (cases 8 and 11), 8q (cases 4 and 10), 17q (cases 10 and 12), and 18q (cases 8 and 11), and losses of chromosome 4/4q (cases 10 and 11), 6q (cases 2 and 10), 7q (cases 8 and 10) and 13 (cases 10 and 11). All other chromosome gains or losses were sporadic.
The fluorescence in situ hybridization (FISH) analysis of the IgH/BCL2 rearrangement was negative in 12 cases; results were confirmed by PCR in four cases (Table 1) .
Interphase FISH experiments (Supplementary Information 2) investigated a cryptic recurrence of either 3q gain or 2q loss in 14 HCV-related lymphomas (Table 1) . When tested with probes encompassing 3q22-q23, a þ 3q was confirmed in 80, 62 and 72% of nuclei in patients 1-3. FISH detected an additional þ 3q positive splenic marginal zone type lymphoma (case 4). In this patient, CGH showed only 8q gain, while FISH detected a 3q trisomy in 15% of nuclei. Double color FISH using probes RP11-944B18 for 8q and RP11-4H14 for 3q clearly showed that the 8q gain at CGH corresponded to tetrasomy 8q in 45% of nuclei and that the 3q gain was an additional change in a small subclone.
Two genes located at 3q and relevant to B-cell lymphomagenesis, BCL6 (3q27) and p63 (3q29), were investigated. Mutational analysis of the BCL6 oncogene was performed in 11 samples by denaturing high-performance liquid chromatography. A two-peak chromatogram, indicative of BCL6 mutation, was obtained in one patient with þ 3q (case 3, Table 1 ). Sequencing showed mutated nucleotide 811 G4A and nucleotide 863 A4G of sequence NC_000003.10, which have not been observed before. None of the five samples with gain of 3q, four from splenic lymphomas (cases 1-4) and one from a patient with type II mixed cryoglobulinemia without lymphoma (see below), expressed significant p63 protein levels. By contrast, two cases of aggressive NHL (cases 8 and 10), both without 3q gain, had high p63 immunoreactivity.
CGH analysis showed loss at chromosome 2q in 5/16 (31%) patients (cases 8-11 and 13, Table 1 ). Interestingly, 4/5 patients (cases 8-11) with 2q loss had histologically and/or clinically aggressive NHL. Patient 8 had MZL with very rapid spleen enlargement; following splenectomy, the lymphoma progressed despite antiviral treatment. Patient 9 had MZL with a large B-cell component, while patient 10 presented with a large B-cell lymphoma. Patient 11 had overt LBCL after low-grade MZL. Array-CGH identified a common deleted region at 2q22.3. Deletion mapping by FISH showed that the two retained probes were CTD-2252P21 and RP11-67J2 at centromeric and telomeric breakpoints, respectively, with a minimum common deletion of 850 kb (Figure 1b) . No cryptic 2q loss was detected in 6/11 cases tested by FISH with probes encompassing 2q22.3, including three cases with a 3q gain (cases 1, 3 and 4).
Six patients with NHL (Table 1 , cases 1, 2, 5, 8, 9, and 16) received antiviral therapy (a-interferon alone or in combination with ribavirin). Lymphoma regression was defined as 470% decrease of peripheral lymphocytosis and/or 430% reduction of the size of involved lymphoid organs. In all six cases, antiviral treatment eradicated HCV. Lymphoma regression was observed in three patients with splenic MZL. Two of them had 3q gain. The three non-responders had clinically aggressive MZL with large B-cell component (cases 8 and 9), and lymphoplasmacytic lymphoma (case 16). Loss of 2q22.3 was found in two of these cases.
In whole PBMC from 19 patients with HCV-associated type II mixed cryoglobulinemia without evidence of NHL, FISH sought 3q gain and 2q loss using probes RP11-548O1 and RP11-4H14 for 3q22.3-q23, and RP11-107E5 and RP11-67J2 for 2q22.3. All samples were negative for 2q loss or 3q gain except one. Using the 3q probes, 34% of nuclei showed three signals in this patient. As the percentage of B cells in this sample was 34.5%, these cells were likely to carry the 3q duplication. Three years later, still in the absence of signs of lymphoma, FISH experiments on purified B cells from freshly isolated PBMC revealed that approximately 80% of B cells carried chromosome 3 duplication, spanning 3p14 (probe RP11-888J3), centromere 3 (probe pa3.5), 3q23 (probe RP11-4H14), and 3q27 (probe ST-1 for BCL6 gene). Flow cytometry analysis showed that 84% of B cells were monoclonal and expressed a VH1-69/kv325-encoded idiotype. Duplication involving also the short arm of chromosome 3, monoclonality and the absence of binuclear lymphocytes (data not shown) allowed us to exclude a polyclonal B-lymphocytosis with iso(3q) in this case.
All 19 patients were negative for IgH/BCL2 rearrangement by FISH.
To our knowledge, this is the first molecular cytogenetic investigation into B-cell lymphomas associated with HCV infection. As a putative signature for lymphomas triggered by HCV, we investigated expression of the VH1-69 and kv325 variable genes by tumor cells. A pathogenetic role for chronic stimulation by HCV is also supported by the observation that all 11 cases tested could be assigned to the antigen-driven memory B cell subset based on CD27 expression, a surrogate marker for mutated memory B-cells.
At variance with prior reports, 4 none of our patients with mixed cryoglobulinemia or NHL resulted positive for t(14;18) at PCR and/or FISH. The discrepancies could be due to different techniques or demographic and genetic backgrounds in patients.
Our CGH and FISH integrated approach found trisomy 3 or partial þ 3q in 60% of splenic MZL. In two cases, the trisomy 3q was associated with other changes. The incidence of trisomy 3q was reported to be typical of low-grade MZL with mutated IgH. 5 Accordingly, all our þ 3q SMZL expressed CD27. These lymphomas had an indolent clinical course and regressed after HCV eradication. These findings suggest that 3q gain is not 'per se' oncogenic, and highlight this anomaly as a marker of clonality rather than of malignancy. Evidence supporting this view derives from our observation of trisomy 3 in nearly all circulating B cells of one patient with mixed cryoglobulinemia in the absence of clinical signs of lymphoma during a 3-year follow-up. Gene(s) in the 3q region might provide a growth/ survival advantage allowing B cells to escape homeostatic Cases studied by FISH and PCR. e Non-responder to antiviral treatment. Bold is used to facilitate the identification of the 3q and 2q rearrangements especially in the presence of complex karyotypes.
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2q loss was found in 80% (4/5 cases) of lymphomas with large B cells. No response to antiviral treatment was observed in this subgroup. In three cases, 2q loss was associated with 1q gain, which has been also found in HCV-related hepatocellular carcinomas. 6 In two of our patients with 2q loss, LBCL was derived from low-grade lymphoma. This progression has previously been observed in MALT-type MZL associated with H. pylori infection. Interestingly, Barth et al.
7 observed 2q deletion in two gastrointestinal MZL with aggressive large B-cell component. Recently, metaphase and array-CGH provided information on the occurrence of 2q loss in diffuse large B-cell lymphomas (up to 16% of cases). 8 We showed that a 2q loss is involved in HCV-related NHL, namely in a subset with progressive disease.
We were able to restrict the minimal common deleted region to 850 kb at 2q22.3 (Figure 1b) . Two interesting genes emerged: (1) a human glycosyltransferase-like domain containing one gene (GTDC1), which catalyzes synthesis of the carbohydrate portion of glycoproteins, glycolipids and proteoglycans, and which is highly expressed in spleen and blood lymphocytes, and, (2) a zinc-finger homeobox 1B (ZFHX1B, also known as KIAA0569; SIP1; SMAD1P1; ZEB2), whose expression in epithelial tumor cells downregulates E-cadherin and induces invasiveness (http://www.ncbi.nlm.nih.gov/).
In conclusion, we identified two distinct genetic events in HCV-driven lymphomagenesis. Gain of 3q is a hallmark of Bcell clonal expansion, as it occurs in low-grade SMZL as well as in the non-malignant lymphoproliferative phase of type II mixed cryoglobulinemia. Conversely, deletion of 850 kb at 2q22.3 is a genomic rearrangement which is associated with more aggressive B-cell lymphomas. Interphase FISH probes for the 2q deleted region have been validated in this study and are available for clinical screening. 
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